Look at Full Prescribing Details OPDIVO® (nivolumab) is indicated for that treatment of Grownup patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed soon after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or following three or more lines of systemic therapy that features autologous HSC